Helus Pharma Inc. (HELP)

Helus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for mental health conditions based on psychedelic-derived compounds. The company was previously known as Cybin Inc. before adopting its current name.

Its pipeline has centered on proprietary molecules designed to provide the therapeutic effects of classic psychedelics with improved properties such as shorter duration and more consistent dosing. Lead programs have included a deuterated psilocybin analog studied in major depressive disorder and a deuterated dimethyltryptamine (DMT) program studied in generalized anxiety disorder, administered alongside psychological support.

The company is based in Toronto, Canada, and its common stock trades on the Nasdaq.